Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revance Therapeutics, Inc. - Common Stock (NQ: RVNC )

3.650 -0.020 (-0.54%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 659,029
Open 3.670
Bid (Size) 3.640 (8)
Ask (Size) 3.650 (2)
Prev. Close 3.670
Today's Range 3.650 - 3.690
52wk Range 2.300 - 7.560
Shares Outstanding 71,829,718
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioAge and Revance and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer
From Revance Therapeutics, Inc.
Via Business Wire

Performance

YTD
+19.28%
+19.28%
1 Month
+18.51%
+18.51%
3 Month
-22.34%
-22.34%
6 Month
-6.89%
-6.89%
1 Year
-38.45%
-38.45%

More News

Read More
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman
Via Business Wire
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Via Benzinga
Topics Government
Exposures Political
Kaplan Fox Alerts Revance Therapeutics, Inc. (RVNC) Investors to a Securities Class Action Lawsuit - Deadline is March 4, 2025
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Kaplan Fox Alerts Revance Therapeutics, Inc. (RVNC) Investors to a Securities Class Action Lawsuit - Deadline is March 4, 2025
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
RVNC DEADLINE: Investors Are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on March 4, 2025
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
RVNC DEADLINE: Investors Are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on March 4, 2025
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Deadline Alert: Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
From Glancy Prongay & Murray LLP
Via Business Wire
RVNC Deadline to Lead in Securities Fraud Lawsuit is March 4, 2025 - Contact Kaplan Fox & Kilsheimer LLP
Via NewMediaWire
Topics Fraud Lawsuit
Exposures Financial Legal
RVNC Deadline to Lead in Securities Fraud Lawsuit is March 4, 2025 - Contact Kaplan Fox & Kilsheimer LLP
Via TheNewswire.com
Topics Fraud Lawsuit
Exposures Financial Legal
Deadline to Lead in Securities Fraud Lawsuit Against Revance Therapeutics, Inc. (RVNC) is March 4, 2025 - Contact Kaplan Fox & Kilsheimer LLP
Via NewMediaWire
Topics Fraud Lawsuit
Exposures Financial Legal
Deadline to Lead in Securities Fraud Lawsuit Against Revance Therapeutics, Inc. (RVNC) is March 4, 2025 - Contact Kaplan Fox & Kilsheimer LLP
Via TheNewswire.com
Topics Fraud Lawsuit
Exposures Financial Legal
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Revance Therapeutics, Inc. (RVNC) - Deadline is March 4, 2025
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Revance Therapeutics, Inc. (RVNC) - Deadline is March 4, 2025
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
Deadline Approaching: Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
From Law Offices of Howard G. Smith
Via Business Wire
REVANCE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Revance Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Law Offices of Frank R. Cruz Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class Action
From Law Offices of Frank R. Cruz
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class Action
From Glancy Prongay & Murray LLP
Via Business Wire
Law Offices of Howard G. Smith Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class Action
From Law Offices of Howard G. Smith
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PWOD, RVNC, B, PSTX on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNC
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, FLIC, RVNC on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.